Dynactin 1 抗体 (AA 251-350) (Cy3)
Quick Overview for Dynactin 1 抗体 (AA 251-350) (Cy3) (ABIN721498)
抗原
See all Dynactin 1 (DCTN1) 抗体适用
宿主
克隆类型
标记
应用范围
-
-
抗原表位
- AA 251-350
-
预测反应
- Human,Mouse,Rat,Dog,Cow,Pig,Horse,Rabbit
-
纯化方法
- Purified by Protein A.
-
免疫原
- KLH conjugated synthetic peptide derived from human DCTN1/Dynactin 1
-
亚型
- IgG
-
-
anti-Dynactin 1 (DCTN1) (C-Term) antibody
Verified DCTN1 适用: 人 WB, ELISA, IHC, IF, FACS 宿主: 山羊 Polyclonal unconjugated
anti-Dynactin 1 (DCTN1) (C-Term) antibodyDCTN1 适用: 人 WB, IF, ICC, IHC (p) 宿主: 兔 Polyclonal unconjugated
anti-Dynactin 1 (DCTN1) (AA 1084-1278) antibodyDCTN1 适用: 人 WB, ELISA, IHC 宿主: 兔 Polyclonal unconjugated
anti-Dynactin 1 (DCTN1) (C-Term) antibodyDCTN1 适用: 人, 小鼠, 大鼠 WB, ELISA, IHC, IF, ICC 宿主: 兔 Polyclonal unconjugated
anti-Dynactin 1 (DCTN1) (AA 945-1139) antibodyDCTN1 适用: 人 WB, IP 宿主: 兔 Polyclonal unconjugated
anti-Dynactin 1 (DCTN1) (N-Term) antibodyDCTN1 适用: 人 WB, IP 宿主: 小鼠 Monoclonal unconjugated
anti-Dynactin 1 (DCTN1) (AA 1216-1278) antibodyDCTN1 适用: 人 WB, IHC, ICC, IHC (p) 宿主: 兔 Polyclonal unconjugated
anti-Dynactin 1 (DCTN1) antibodyDCTN1 适用: 人, 小鼠, 大鼠 IF 宿主: 兔 Polyclonal unconjugated
anti-Dynactin 1 (DCTN1) (AA 1-198) antibodyDCTN1 适用: 人 WB, ELISA 宿主: 小鼠 Monoclonal 2E4-1C2 unconjugated
anti-Dynactin 1 (DCTN1) (C-Term) antibodyDCTN1 适用: 人, 小鼠, 大鼠, Cow, 犬, 马, 豚鼠, 兔, 斑马鱼 WB 宿主: 兔 Polyclonal unconjugated
-
-
应用备注
-
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200 -
限制
- 仅限研究用
-
-
-
状态
- Liquid
-
浓度
- 1 μg/μL
-
缓冲液
- Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.
-
储存液
- ProClin
-
注意事项
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
-
储存条件
- -20 °C
-
储存方法
- Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
-
有效期
- 12 months
-
-
- Dynactin 1 (DCTN1)
-
别名
- DCTN1
-
背景
-
Synonyms: Alternative names150 kDa dynein associated polypeptide, 150 kDa dynein-associated polypeptide, DAP 150, DAP-150, DAP150, DCTN 1, DCTN1, DCTN1_HUMAN, DP 150, DP-150, DP150, Dynactin 1 p150 Glued Drosophila homolog, Dynactin 1 p150 glued homolog Drosophila, Dynactin 1, Dynactin subunit 1, Dynactin1, HMN7B, P135, p150 Glued Drosophila homolog, p150 glued, p150 glued homolog, p150GLUED DROSOPHILA HOMOLOG OF, p150-glued, p150glued.
Background: Required for the cytoplasmic dynein-driven retrograde movement of vesicles and organelles along microtubules. Dynein-dynactin interaction is a key component of the mechanism of axonal transport of vesicles and organelles.Tissue specificity, Brain.Involvement in disease, Defects in DCTN1 are the cause of distal hereditary motor neuronopathy type 7B (HMN7B), also known as progressive lower motor neuron disease (PLMND). HMN7B is a neuromuscular disorder. Distal hereditary motor neuronopathies constitute a heterogeneous group of neuromuscular disorders caused by selective degeneration of motor neurons in the anterior horn of the spinal cord, without sensory deficit in the posterior horn. The overall clinical picture consists of a classical distal muscular atrophy syndrome in the legs without clinical sensory loss. The disease starts with weakness and wasting of distal muscles of the anterior tibial and peroneal compartments of the legs. Later on, weakness and atrophy may expand to the proximal muscles of the lower limbs and/or to the distal upper limbs.Defects in DCTN1 are a cause of susceptibility to amyotrophic lateral sclerosis (ALS). ALS is a neurodegenerative disorder affecting upper and lower motor neurons, and resulting in fatal paralysis. Sensory abnormalities are absent. Death usually occurs within 2 to 5 years. The etiology is likely to be multifactorial, involving both genetic and environmental factors.Defects in DCTN1 are the cause of Perry syndrome (PERRYS), also called parkinsonism with alveolar hypoventilation and mental depression. Perry syndrome is a neuropsychiatric disorder characterized by mental depression not responsive to antidepressant drugs or electroconvulsive therapy, sleep disturbances, exhaustion and marked weight loss. Parkinsonism develops later and respiratory failure occurred terminally.
-
基因ID
- 1639
-
途径
- M Phase, ER-Nucleus Signaling
抗原
-
